NMDS Group logo

NMDS Group


Sponsor : Nordic MDS group

Principal investigator:  Eva Hellström-Lindberg, Lars Möllgård

Primary endpoints:  Cytogenetic respons (FISH) after 16 weeks

Status: Final protcol May 9, 2007. Closed for inclusion November, 2009.

Start: October, 2007.

Research support:  Nordic Cancer Union, Celgene

Inclusion criteria:

  • MDS (IPSS Int-2 or High) or AML (de novo or secondary) with a karyotype including del(5q) or monosomy 5.

Patients could be included if:

  •  At diagnosis and not considered eligible for induction chemotherapy.
  •  Refractory to induction therapy
  •  Relapse and not considered eligible for reinduction.
  •  Relapse after allogeneic stem cell transplantation and not considered sutiable for reinduciton chmotherapy or other conventional therapy.

Exclusion criteria:

  •  Patients who are eligible for curative treatment
  •  Prior therapy with lenalidomide

Treatment:  Oral Lenalidomide in increasing doses for 16 weeks

Contact person: Lars Möllgård, This email address is being protected from spambots. You need JavaScript enabled to view it.

Article: Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E. 2011, Haematologicahttps://www.ncbi.nlm.nih.gov/pubmed/?term=21719884.